Chronic immune thrombocytopenia (ITP) is an autoimmune blood disorder in which your immune system mistakenly attacks and destroys your own platelets, keeping your platelet count persistently low for longer than 12 months. ITP is classified by how long it lasts: newly diagnosed covers the first three months, persistent describes the period from 3 to 12 months, and chronic means symptoms have continued beyond a full year. About 10 in every 100,000 people live with chronic ITP, with new cases developing at a rate of 2 to 4 per 100,000 each year. The condition is more common in adults over 60.
Why Your Body Destroys Its Own Platelets
In a healthy immune system, antibodies target foreign invaders like bacteria and viruses. In ITP, a specific type of antibody (IgG) locks onto the surface of platelets, essentially tagging them for destruction. Your spleen, which filters the blood, recognizes these tagged platelets and removes them far faster than your bone marrow can replace them.
Antibodies aren’t the only problem. Some patients also have immune cells that directly kill platelets without antibodies being involved at all. Researchers have found that people with ITP show imbalances in the types of immune cells that regulate this process, including fewer of the “braking” cells (called T-regulatory cells) that normally prevent the immune system from attacking your own tissues. This combination of overactive immune attack and weakened immune regulation is what makes chronic ITP so persistent.
Symptoms and What They Look Like
Some people with chronic ITP have no obvious symptoms at all, especially when platelet counts are only mildly low. When counts drop further, bleeding becomes harder to stop, and it can show up in several ways:
- Petechiae: tiny, flat red dots on the skin caused by blood leaking from small vessels, often on the lower legs
- Purpura: larger patches of red, purple, or brownish-yellow discoloration from bleeding under the skin
- Hematomas: lumps of clotted blood beneath the skin that feel like bruises with a raised center
- Mucosal bleeding: frequent nosebleeds, bleeding gums, blood in urine or stool, or unusually heavy menstrual periods
Beyond bleeding, fatigue is one of the most common and underappreciated symptoms. A study of 175 adults with ITP found that both fatigue and overall quality of life were significantly impaired. Fatigue often improved during active treatment but worsened again three months after discharge, suggesting it’s a persistent challenge rather than something that resolves once platelet counts stabilize.
How Chronic ITP Is Diagnosed
There is no single test that confirms ITP. Instead, it’s a diagnosis of exclusion. Your doctor rules out other causes of low platelets, including infections, medication side effects, liver disease, and other autoimmune conditions, through blood work and a review of your medical history. If no other explanation is found and your platelet count remains low, ITP is the working diagnosis. The “chronic” label applies only after the condition has persisted beyond 12 months.
First-Line Treatments
Corticosteroids are the standard starting treatment. They work by dialing down the immune system’s attack on platelets. A typical course lasts two to four weeks and is then gradually tapered. An alternative approach uses short, high-intensity pulses of steroids given over four days, repeated in cycles. Both approaches aim to raise the platelet count enough to reduce bleeding risk while minimizing side effects from prolonged steroid use.
When platelet counts need to come up quickly, such as during active bleeding, intravenous immunoglobulin (IVIG) can raise counts faster than steroids alone. It’s given as a single infusion and repeated if needed based on how your platelets respond. IVIG is also used as a bridge for people who can’t tolerate steroid side effects or who need something to hold them over while transitioning to a longer-term treatment.
When First-Line Treatment Isn’t Enough
Many people with chronic ITP don’t maintain a stable platelet count on steroids alone. At that point, several second-line options come into play.
Splenectomy
Removing the spleen eliminates the main site where tagged platelets are filtered out and destroyed. It remains one of the most effective long-term options. In one comparative study, 83% of patients who had a splenectomy achieved a complete initial response, and 74% still maintained that response at five years. The tradeoff is that it’s a permanent, irreversible surgery, and living without a spleen increases your long-term vulnerability to certain infections.
Rituximab
Rituximab works by depleting the immune cells that produce the harmful antibodies attacking your platelets. It may also help normalize the dysfunctional immune cells involved in the disease. About 44% of patients achieve a complete response initially, and roughly 52% maintain their response at five years. Those numbers are lower than splenectomy, but rituximab avoids surgery and preserves the spleen.
Platelet Growth Stimulators
A newer class of medications takes a different approach entirely. Instead of trying to stop platelet destruction, these drugs stimulate your bone marrow to produce more platelets to compensate for the loss. They’re available in both oral tablet form and as a weekly injection. These medications are taken on an ongoing basis and require regular blood monitoring to keep platelet counts in a safe range without going too high.
Serious Bleeding Risks
The most dangerous complication of chronic ITP is bleeding inside the brain. This occurs in roughly 1.5% of all ITP patients and carries a 34% mortality rate. The risk is highest when platelet counts are extremely low. This is why treatment decisions in chronic ITP aren’t just about numbers on a lab report. They’re about keeping your count high enough to prevent a rare but potentially fatal event, while balancing the side effects of ongoing therapy.
Living With Chronic ITP
Chronic ITP is, by definition, a long-haul condition. Many people cycle through periods of relatively stable counts and periods where counts drop and treatment needs to be adjusted. The fatigue that comes with the disease can be just as limiting as the bleeding risk itself. Research shows that quality of life does tend to improve over time with treatment, but the improvement is gradual and uneven.
Day-to-day management often involves learning to recognize early signs of a drop in platelets, like new petechiae or increased bruising, and staying in regular contact with a hematologist who can adjust your treatment plan. Contact sports and activities with high injury risk are generally avoided when counts are low. Many people with chronic ITP lead full, active lives, but it requires ongoing attention and a treatment plan tailored to how your body responds.